Ipca on recovery path over FDA clearance, growth in Africa tender business

The stock was trading at 17 times its 2020 earnings estimates

Ipca Laboratories' stock is an outperformer in the pharmaceutical sector, gaining over 60 per cent in the last six months. The street's confidence in the stock has increased because its plant remediation process, which began in the 2015, is coming to an end. The company has also been reinstated as a supplier for the Africa tender business. 

The firm, whose annual revenue has stagnated at Rs 30 billion over the last three years, after the US Food and Drug Administration (US FDA) ban in 2015, is expected to witness a revival of its top line. Signs of improvement were visible